Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Published:2015-03 Issue:9972 Volume:385 Page:956-965
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Neuschwander-Tetri Brent A,Loomba Rohit,Sanyal Arun J,Lavine Joel E,Van Natta Mark L,Abdelmalek Manal F,Chalasani Naga,Dasarathy Srinivasan,Diehl Anna Mae,Hameed Bilal,Kowdley Kris V,McCullough Arthur,Terrault Norah,Clark Jeanne M,Tonascia James,Brunt Elizabeth M,Kleiner David E,Doo Edward

Funder

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Center for Advancing Translational Sciences (NCATS) for NASH CRN Studies

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States;Marrero;Hepatology,2002

2. NASH and HCC;Page;Clin Liver Dis,2009

3. Population-based risk factors and resource utilization for HCC: US perspective;Sanyal;Curr Med Res Opin,2010

4. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic;Agopian;Ann Surg,2012

5. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications;Cusi;Gastroenterology,2012

Cited by 1860 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Avaliação comparativa das análises histológicas de esteatose experimental, realizadas por acadêmicos treinados e patologista;Cuadernos de Educación y Desarrollo;2024-09-05

3. Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?;Digestive and Liver Disease;2024-09

4. Apigenin-6-C-glucoside ameliorates MASLD in rodent models via selective agonism of adiponectin receptor 2;European Journal of Pharmacology;2024-09

5. NAD deficiency contributes to progressive kidney disease in HIV-nephropathy mice;American Journal of Physiology-Renal Physiology;2024-09-01